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INTRODUCTION 
Pneumonia is acute inflammation of the lung parenchyma usually 
caused by infections. There is no universally accepted definition of pneumonia 
worldwide. Indian classifications define it based on history of respiratory 
symptoms and clinical findings. WHO has defined pneumonia solely based on 
clinical findings based on respiratory rate and presence of chest retractions. (1) 
The incidence of pneumonia in children below 5 years is estimated to be 
0.29 episodes/child-year in developing countries. There are about 156 million 
new episodes each year worldwide. Among the developing world, India shares 
the highest burden with 43 million new episodes of pneumonia every year 
followed by China, Pakistan, Bangladesh and Indonesia (2). Among all 
community cases, 7-13% are severe enough to be life threatening and require 
hospitalization killing more than 2 million children every year. Pneumonia is a 
substantial cause of morbidity and mortality among children less than 5 years 
of age.  
Recent estimates from the World Health Organization suggest that 
pneumonia is responsible for 19% of deaths in the above age group, leading to 
nearly 3 million deaths per year. Of these deaths, two thirds occur during 
infancy and more than 90% occur in the developing countries. In India, recent 
estimates in under-fives suggest that 13% of deaths and 24% of National 
Burden of Disease is due to pneumonia (3). Hospital based studies have 
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reported that 20–30% of admissions in under-fives are due to pneumonia. Case 
fatality rates in hospitalized children are reported to be between 8.7–47% (4). 
Various interventions have been done by the World Health Organization 
(WHO) to reduce pneumonia related morbidity and mortality. Acute 
Respiratory Infection (ARI) control program was initiated in 1983, which 
includes identification of children with pneumonia by clinical features (rapid 
respiration and difficulty in breathing) and administration of antimicrobials 
with a presumption that majority of pneumonia in developing countries is 
because of bacterial pathogens, which led to a decline in the infant mortality 
rate by 10.7 (4.8–16.7) deaths per 1000 live births and decline in the mortality 
of under-fives by 36 deaths per 1000 live births.(5) 
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ETIOLOGY 
Pneumonia can be caused by infectious and non- infectious agents. Most 
cases of pneumonia are caused by microorganisms like bacteria, viruses, fungi 
etc. The non-infectious causes include aspiration, foreign bodies, hydrocarbons, 
hypersensitivity reactions and drug/ radiation induced (4,5). 
The common causes of pneumonia according to age are shown in table 1 
below: 
AGE GROUP COMMON CAUSES 
OF PNEUMONIA 
LESS COMMON 
CAUSE OF 
PNEUMONIA 
<2 months Klebsiella,Ecoli, 
staphylococci,gram 
negative bacteria 
Pneumococci 
H influenza 
Anaerobic organisms 
2 months to 5 years Bacteria: 
Pneumococci,H. 
influenza, staph aureus, 
Klebsiella 
Viruses: 
Respiratory syncytial 
virus, 
Parainfluenza virus, 
Influenza virus 
M.Tuberculosis, 
N.Menigitidis, Measles, 
Varicella zoster 
>5 years Pneumococci, 
Mycoplasma, 
Chlamydia 
H influenza, S.aureus, 
M.Tuberculosis, 
adenovirus, EBV 
  
Table 1: causative organisms of pneumonia 
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In children with HIV, bacteria remain the most common causative 
organism in pneumonia, but additional pathogens like Pneumocystis jiroveci 
should be considered particularly in children with low CD4 counts. Other 
causes in children include mycobacterium, fungal infections and viral 
infections. (6) 
Pertussis should be considered in all infants with community acquired 
pneumonia especially if immunization is not complete. Mycobacterium 
tuberculosis can cause pneumonia in children if they are exposed to adults with 
the disease (7). 
 Risk factors related to the host and the environment that affect incidence 
of childhood clinical pneumonia in the community in developing countries (4) 
Definite risk factors  
Malnutrition (weight-for-age z-score < –2)  
Low birth weight (≤ 2500 g)   
Non-exclusive breastfeeding (during the first 4 months of life)   
Lack of measles immunization (within the first 12 months of life)   
Indoor air pollution  
Crowding  
Likely risk factors  
Parental smoking  
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Zinc deficiency  
Mother’s experience as a caregiver  
Concomitant diseases (e.g. diarrhea, heart disease, asthma)   
Possible risk factors  
Mother’s education  
Day-care attendance  
Rainfall (humidity) 
High altitude (cold air)   
Vitamin A deficiency  
Birth order  
Outdoor air pollution 
PATHOGENESIS: 
Pneumonia results from inflammation of the alveolar space and may 
compromise air exchange. While often complicating other lower respiratory 
infections such as bronchiolitis or laryngotracheobronchitis, pneumonia may 
also occur via hematogenous spread or aspiration. Most commonly, this 
inflammation is the result of invasion by bacteria, viruses, or fungi, but it can 
occur as a result of chemical injury or may follow direct lung injury (e.g., near 
drowning). (8) 
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Four stages of lobar pneumonia have been described. In the first stage, 
occurring within 24 hours of infection, the lung is characterized 
microscopically by vascular congestion and alveolar edema. Many bacteria and 
few neutrophils are present. The stage of red hepatization (2-3 days), so called 
because of its similarity to the consistency of liver, is characterized by the 
presence of many erythrocytes, neutrophils, desquamated epithelial cells, and 
fibrin within the alveoli. (9,10) 
In the stage of grey hepatization (2-3 days), the lung is gray-brown to 
yellow because of fibrino-purulent exudate, disintegration of red cells, and 
hemosiderin. The final stage of resolution is characterized by resorption and 
restoration of the pulmonary architecture. Fibrinous inflammation may extend 
into the pleural space, causing a rub heard by auscultation, and it may lead to 
resolution or to organization and pleural adhesions.  Bronchopneumonia, a 
patchy consolidation involving one or more lobes, usually involves the 
dependent lung zones, a pattern attributable to aspiration of oropharyngeal 
contents. The neutrophilic exudate is centered in bronchi and bronchioles, with 
centrifugal spread to the adjacent alveoli (9). 
 In interstitial pneumonia, patchy or diffuse inflammation involving the 
interstitium is characterized by infiltration of lymphocytes and macrophages. 
The alveoli do not contain significant exudates, but protein-rich hyaline 
membranes similar to those found in adult respiratory distress syndrome 
(ARDS) may line the alveolar spaces. Bacterial super infection of viral 
pneumonia can also produce a mixed pattern of interstitial and alveolar air 
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space inflammation.  Miliary pneumonia is a term applied to multiple, discrete 
lesions resulting from the spread of the pathogen to the lungs via the 
bloodstream. 
 The lower respiratory tract is normally kept sterile by physiologic 
defense mechanisms, including the muco-ciliary clearance, the properties of 
normal secretions such as secretory immunoglobulin A and clearing of the 
airway by coughing. Immunologic defense mechanisms of the lung that limit 
invasion by pathogenic organisms include macrophages present in alveoli and 
bronchioles, secretory IgA and other immunoglobulins. Viral pneumonia 
usually results from spread of infection along the airways, accompanied by 
direct injury of the respiratory epithelium resulting in airway obstruction from 
swelling, abnormal secretions, and cellular debris. The small caliber of airways 
in young infants makes them particularly susceptible to severe infection. 
Atelectasis, interstitial edema, and ventilation perfusion mismatch causing 
significant hypoxemia often accompany airway obstruction. It can also 
predispose to secondary bacterial infection by disturbing normal host defense 
mechanisms, altering secretions and modifying the bacterial flora (11,12) 
When bacterial infection is established in the lung parenchyma, the 
pathologic process varies according to the invading organism. Streptococcus 
pneumoniae produces local edema that aids in the proliferation of organisms 
and their spread into adjacent portions of lung often resulting in the 
characteristic lobar involvement.  S. aureus pneumonia manifests in confluent 
bronchopneumonia which is often unilateral and characterized by presence of 
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extensive areas of hemorrhagic necrosis and irregular areas of cavitation of the 
lung parenchyma, resulting in pneumatocoeles, empyema or at times 
bronchopulmonary fistulas. (9) 
Mycoplasma pneumoniae attaches to the respiratory epithelium, inhibits 
ciliary action and leads to cellular destruction and an inflammatory response in 
the submucosa. As the infection progresses, sloughed cellular debris, 
inflammatory cells, and mucus cause airway obstruction, with spread of 
infection occurring along the bronchial tree as it does in viral pneumonia. 
(5,11) 
CLINICAL FEATURES: 
Children with pneumonia may present with fever with/ without chills, 
cough, fast breathing and in severe cases with chest retractions, 
nasalflaring,lethargy, irritability, inability to feed. Very severe cases may 
present with respiratory failure. Among these, fever and fast breathing are most 
consistent features. The atypical manifestations include vomiting, diarrhea, 
abdominal pain, neck retractions in younger children. 
Children with bacterial pneumonia have very highgrade fever, chills, 
productive cough and systemic manifestations in the form of sepsis. Rapid 
progression is characteristic of bacterial pneumonia; wheezing is not a feature 
of bacterial pneumonia. Children with viral pneumonia may have a prodrome 
of symptoms like cough and rhinitis later developing fast breathing and 
wheezing. Children with mycoplasma and chlamydia infection may have 
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gradual onset head ache,malaise, non -productive cough, low grade fever and 
rhonchi (13) 
The physical examination findings depend on the severity, stage of 
pneumonia and associated complications. Early in the course of illness 
decreased breath sounds, with crackles and rhonchi may be present on the 
affected lung fields. 
With increasing consolidation or development of pleural effusion, 
pyothorax and pyopneumothorax, there will be dull note on percussion. Other 
physical abnormalities include paralytic ileus, neck rigidity and abdominal 
distension. 
Differences between bacterial and viral pneumonia is shown in table  
2 below : (14) 
FEATURES BACTERIAL 
PNEUMONIA 
VIRAL PNEUMONIA 
ONSET Abrupt Gradual 
EPIDEMIC Not seen Common 
ASSOCIATED 
CONDITIONS 
Sepsis Associated with URI, 
coryza 
FEVER High grade May be absent 
TOXEMIA Common Absent 
RESPIRATORY 
DISTRESS 
Common Absent 
LUNG SIGNS Crackles++ Wheeze++ 
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CXR Confluent infiltrates. Diffuse in peripheral 
areas. 
PLEURAL 
INVOLVEMENT 
May be seen Not common 
PROGNOSIS Complications can be 
seen like empyema, 
pneumatocoele. 
Usually self-limiting. 
Resolves in a week. 
Hyperinflation can be 
seen 
   
Table 2: Differences between bacterial and viral pneumonia 
DIAGNOSIS: 
Pneumonia is usually a clinical diagnosis. The utility of various clinical 
features in making the diagnosis of pneumonia has been studied. Tachypnea is 
the most consistent useful sign of pneumonia with sensitivity of 64-81%. It has 
the advantage of high reproducibility, very less interpersonal variability and 
does not needhigh expertise and hence can be used at the community level by 
health workers in making the diagnosis of pneumonia. (15) 
Chest indrawing has the sensitivity of 17-35% and specificity of 82-84% 
in identifying pneumonia. Auscultatory signs have lower sensitivity and 
specificity and poor reproducibility. Crackles are 43-57% sensitive and 75-80% 
specific in identifying pneumonia in the community. These criteria may not be 
useful in malnourished children. (9,16) 
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Fall in saturation or cyanosis is generally a late sign and may not help in 
diagnosing pneumonia and when present, it indicates severe pneumonia. 
Normal oxygen saturation does not correlate with milder disease. 
In developing countries like India, the diagnosis of pneumonia is based 
on the WHO’s age specific criteria for tachypnea which can also be used at 
community level for diagnosis and referral. 
Diagnosis of tachypnea in the various pediatric age groups 
Age - respiration rate (breaths/min) 
0-2months ≥ 60 
2-12months ≥ 50 
1-5years ≥ 40 
Chest X-ray is done to confirm the diagnosis. The CXR in viral 
pneumonia is characterized by hyperinflation, bronchial wall thickening and 
focal areas of atelectasis. Confluent lobar consolidation is consistent with 
pneumococcal pneumonia. Chest X-ray does not differentiate causative agents 
of pneumonia.Since CXR does not change the course of pneumonia,it is not 
recommended for the diagnosis of pneumonia.It should be reserved for children 
with ambiguous findings, persistent pneumonia, pneumonia that is 
unresponsive to antibiotics and those with suspected complications like pleural 
effusion. (17) 
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For rational treatment of pneumonia, causative organism must be 
identified by clinical features or rapid and less expensive laboratory tests. It is 
not easy to distinguish bacterial and viral pneumonias based on clinical features 
and CXR findings. Bacterial pneumonia in children is associated with moderate 
to high grade fever, polymorph nuclear response in blood, increased level of 
acute phase reactants like pro-calcitonin and C-reactive proteins in blood and 
alveolar consolidation on radiographs on chest. Viral pneumonia is associated 
with young age, breathlessness and wheezing. However, all the clinical features 
and laboratory tests do not have desirable sensitivity and specificity to use them 
in clinical practice. (11) 
The common methods used for the identification of the etiological 
agents include blood culture, lung puncture, nasopharyngeal aspirates, 
immunoassays of blood and urine. All these methods have their own 
drawbacks. The blood culture is not a reliable investigation because of its lower 
yield (ranging from 5% to 30% in various studies) in bacterial pneumonias. 
(15) Lung puncture is an invasive procedure associated with high incidence of 
pneumothorax and pulmonary hemorrhage and hence cannot be performed 
routinely in all cases. Nasopharyngeal aspirates can be used for the isolation of 
viruses, chlamydia, and mycoplasma, but a possibility of concomitant bacterial 
pneumonia cannot be ruled out with confidence. There are various 
immunoassays for identifying bacteria, viruses, mycoplasma, chlamydia and P. 
jiroveci but are expensive and need standardization in community studies. (15) 
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In view of difficulties faced with identification of organisms, the high 
cost and lack of availability of the investigations, the laboratory tests are not 
ordered routinely for the diagnosis of CAP. Most of the cases are diagnosed on 
clinical grounds and treated accordingly. In children with poor response, 
underlying systemic disease and immunocompromised hosts, an aggressive 
attempt should be made to identify etiological agents. 
CLASSIFICATION OF PNEUMONIA: 
In developing world, in view of very high incidence of pneumonia it is 
recommended to make the diagnosis of pneumonia at community level based 
on clinical features alone (14).According to IMCI (Integrated management of 
childhood illness), pneumonia is classified as 
No pneumonia: 
  No fast breathing and no indication of severe and very severe 
pneumonia. 
Pneumonia:  
Fast breathing and no indication of severe and very severe pneumonia 
Severe pneumonia: 
 lower chest indrawing or nasal flaring and no sign of very severe 
pneumonia. 
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Very severe pneumonia: 
Central cyanosis, or not able to breastfeed or drink or convulsions, or 
lethargy or unconsciousness or severe respiratory distress (2). 
 Figure 1 shows the IMNCI classification of pneumonia: 
 
             Figure 1: Classification of pneumonia (IMNCI classification) 
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Recently in 2015, WHOpublished the revised the classification and 
treatment of childhood pneumonia at health facilities. The new classification is 
therefore simplified to include only two categories of pneumonia, “pneumonia” 
with fast breathing and/or chest indrawing which requires home therapy with 
oral amoxicillin and “severe pneumonia”, pneumonia with any general danger 
sign, which requires referral and injectable drug therapy.(23) 
Figure 2 shows the recent WHO classification of pneumonia: 
 
                Figure 2: Recent WHO classification of pneumonia 
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The following figure shows the difference between the previous and 
recent WHO classification of pneumonia: 
 
          Figure 3: Difference between previous and latest WHO classification 
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Table 3 showing classification of pneumonia according to WHO and IMNCI: 
WHO IMNCI 
Pneumonia – fast breathing and chest 
indrawing pneumonia. 
No pneumonia: no fast breathing and 
no indication of severe and very severe 
pneumonia. 
Severe pneumonia- pneumonia with 
danger signs- 
 Central cyanosis 
 Not able to breastfeed or drink              
convulsions 
 Lethargy 
 Unconsciousness 
 Severe respiratory distress. 
Pneumonia: fast breathing and no 
indication of severe and very severe 
pneumonia. 
 Severe pneumonia : lower chest 
indrawing or nasal flaring and no sign 
of very severe pneumonia. 
 Very severe pneumonia: 
 Central cyanosis 
 Not able to breastfeed or drink              
convulsions 
 Lethargy 
 Unconsciousness 
 Severe respiratory distress 
 
               Table 3: WHO and IMNCI classification of pneumonia 
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MANAGEMENT: 
In developing world, in view of very high incidence of pneumonia it is 
recommended to make the diagnosis of pneumonia at community level based 
on clinical features alone. The diagnostic criteria suggested by WHO are very 
cost effective for CAP. There is no indication for any test in a child with 
suspected community acquired pneumonia. Children with non-severe 
pneumonia with no danger signs should be treated on outpatient basis with oral 
antibiotics and antipyretics. 
SELECTION OF ANTIBIOTIC: 
Administration of appropriate antibiotic in early period of pneumonia 
alters the outcome of the disease particularly when the causative organism is 
bacteria. Antibiotics may not have role in pneumonia caused by viruses. 
Unnecessary antibiotics administration in children may lead to selection of 
resistant organism and thus promotes drug resistance and serious illness in the 
future. However, in view of public health implications of better outcome of 
pneumonias by early administration of antibiotics and lack of reliable 
laboratory test in identification of causative agents, antibiotics are administered 
empirically in most instances. Treatment decisions are made based on child’s 
age and epidemiological factors. Factors that helps in choosing appropriate 
antibiotics are 
1.Knowledge of etiological agents 
2.Sensitivity of pathogens to antibiotics. 
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3. Immune status 
4. Nutritional status 
5. Previous antibiotics used in recent past 
6.History of hospitalization, duration of illness. 
7. Associated illnesses 
8. Cost and safety of antibiotics. 
LIKELY ETIOLOGICAL AGENTS: 
The common etiological agents of pneumonia in children below 2 
months include gram negative bacilli. In children between 2 months- 5 years, it 
is commonly caused by S. pneumoniae, Staphylococcus aureus and atypical 
organisms. In children above 5 years, the common agents are S.pneumoniae, 
Staphylococcus aureus and mycoplasma.(8) 
SENSITIVITY OF PATHOGENS: 
Common etiological agents including S. pneumoniae and H. influenza 
are sensitive to wide range of antibiotics including semi synthetic penicillin 
(amoxicillin, ampicillin), cephalosporins (cephalexin,cefaclor, cefuroxime), 
macrolides (erythromycin, azithromycin, roxithromycin), cotrimoxazole and 
chloramphenicol. Gram negative bacilli are sensitive to ampicillin, 
aminoglycosides and cephalosporins. 
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Atypical organisms such as chlamydia and mycoplasma are sensitive to 
macrolides and tetracycline. The latter is not used in children below 8 years of 
age. Thus, macrolides are the drug of choice for the treatment of atypical 
organisms. Newer quinolones such as gatifloxacin and levofloxacin have an 
advantage of good coverage for S. pneumoniae. However, their use in children 
is limited and need more trials.(9) 
SEVERITY OF ILLNESS: 
In most circumstances, microbial etiology of pneumonia remains similar 
despite varying degree of severity of illness. However, it is logical to select 
most appropriate antibiotics that have lesser chance of failure due to possible 
resistant organisms in more severe disease. 
UNDERLYING DISEASE: 
Knowledge about the underlying disease is essential in selecting 
antibiotic as many chronic diseases have special predilection to particular 
organisms. Children with hemoglobinopathies or nephrotic syndrome are more 
susceptible to pneumococcal organisms.A child with cystic fibrosis is more 
likely to have infection with staphylococcus,H. influenza or pseudomonas. A 
child with HIV infection may be due to gram negative bacilli, P. jiroveci or 
fungi in addition to usual pathogens. The progression of disease is rapid in this 
group due to immunodeficiency and hence most efficient antibiotic 
combinations are used as first line treatment (10).  Children with neutropenia 
should be treated with antibiotics that are effective against gram- negative 
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bacilli, staphylococcus along with common pathogens like S. pneumoniae, and 
H. influenza. Hence the drug of choice may be ceftazidime with 
aminoglycosides with/ without cloxacillin or vancomycin.(16,17) If patient 
does not respond over 2-3 days, the next may be to consider antifungal 
antibiotics and treatment of P. jiroveci pneumonia. 
NUTRITIONAL STATUS: 
Malnourished children are predisposed to more frequent and severe 
episodes of pneumonia. The etiology of pneumonia in malnourished children is 
generally similar to that in well nourished, with an added predisposition for 
gram negative organisms. Pneumonia in malnourished children may progress to 
severe disease rapidly. The symptoms of pneumonia may be masked in 
severely malnourished children possibly due to a blunted inflammatory 
response (18). 
PREVIOUS ANTIBIOTICS: 
History of antibiotics for the current episode or in the recent past 
(previous 2-4 weeks) may give an idea about possible resistant organisms. If a 
patient had received repeated course of antibiotics patient’s microbial flora may 
be resistant to those antibiotics. If a patient has already received cotrimoxazole 
or amoxicillin, it is better to give amoxicillin –clavulanate, cefuroxime or 
cefpodoxime rather than giving some antibiotics. (18) 
  
22 
 
HISTORY OF HOSPITALIZATION: 
After hospitalization the microbial flora of the patient changes to gram 
negative bacilli. Hence, pneumonia in hospitalized child or hospitalized in 
recent past is more likely to be due to gram negative bacilli. The staphylococcal 
infection in hospital setting is likely to be resistant to penicillin and needs 
vancomycin or linezolid. In such situations, cefuroxime or amoxicillin-
clavulanic acid may be used as primary drugs in non -severe illness and 
combination of quinolone or third-generation cephalosporin with vancomycin 
may be used in severe pneumonia. 
DURATION OF ILLNESS: 
A short duration of illness suggests a possible bacterial etiology. 
Prolonged illness of more than 2 weeks may be due to infection with M. 
tuberculosis, atypical organism or certain viral infections like adenovirus. 
INDICATIONS FOR INTRAVENOUS ANTIBIOTIC THERAPY: 
Intravenous antibiotic therapy is warranted if the child has severe 
pneumonia, disturbed consciousness, improper swallowing, frequent vomiting 
and suspected drug malabsorption. Switch to oral when the child starts 
accepting orally and shows significant clinical improvement. Complete 
intravenous therapy is needed if the patient is newborn. 
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The revised guidelines proposed by WHO in 2015 (23) for the 
management of community acquired pneumonia are 
1) Children with fast breathing pneumonia with no chest in drawing or 
general danger signs should be treated with oral amoxicillin at least 40 
mg/kg/dose twice daily (80 mg/kg/day) for five days. In areas with low 
HIV prevalence give amoxicillin for 3 days. 
Children with fast breathing pneumonia who fail on first line treatment 
with amoxicillin should have the option of referral to a facility where 
there is appropriate second line treatment. 
2) Children aged 2-59 months with chest indrawing pneumonia should be 
treated with oral amoxicillin at least 40 mg/kg/dose twice daily(80 
mg/kg/day) for five days. 
3) Children aged 2-59 months with severe pneumonia should be treated 
with parenteral ampicillin and gentamicin as first line treatment. 
Ampicillin 50mg/kg or benzyl penicillin 50,000 units/kg IM/IV every 
six hours for at least 5 days and gentamicin 7.5mg/kg IM/IV once a day 
for at least 5 days. Ceftriaxone should be used as a second line treatment 
in children with severe pneumonia having failed on first line treatment. 
4) Ampicillin (penicillin when ampicillin is not available) plus gentamicin 
or ceftriaxone are recommended as a first line treatment for HIV 
infected and exposed infants and for children under 5 years of age with 
chest indrawing pneumonia or severe pneumonia.For HIV infected and 
exposed infants and for children with chest indrawing pneumonia or 
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severe pneumonia, who do not respond to treatment with ampicillin or 
penicillin plus gentamicin, ceftriaxone alone is recommended for use as 
second line treatment. 
5) Empiric cotrimoxazole treatment for suspected pneumocystis jiroveci 
pneumonia is recommended as an additional treatment for HIV infected 
and exposed children aged from 2 months-1 year with severe and very 
severe pneumonia. Empirical cotrimoxazole treatment for pneumocystis 
jiroveci is not recommended for HIV infected and exposed children over 
1 year of age with chest indrawing or severe pneumonia. 
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MANAGEMENT OF PNEUMONIA ACCORDING TO INDIACLEN 
TASK FORCE ON PNEUMONIA: (2) 
Pneumonia: 
 
Cotrimoxazole5-7 mg/kg/day for 5 days or amoxicillin 30-40 mg/kg/day 
in 2-3 divided doses for 3 days. 
 
Severe pneumonia: 
Admission- iv ampicillin 50 mg/kg every 6 hours, Inj.Gentamicin to be 
added after 48 hrs. if no improvement. 
 
Very severe pneumonia: 
Iv ampicillin 50 mg/kg every 6 hourly and inj. Gentamicin 7.5 
mg/kg/day once a day is started together. 
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The table 4 compares the treatment of pneumonia according to WHO and 
INDIACLEN task force of pneumonia: (2,23) 
 
WHO INDIACLEN TASK FOCE ON 
PNEUMONIA 
Pneumonia-oral amoxicillin 40 
mg/kg/ dose twice daily for 5 days 
 
Pneumonia- cotrimoxazole5-7 
mg/kg/day  for 5 days or amoxicillin 
30-40 mg/kg/day in 2-3 divided doses 
for 3 days 
Severe pneumonia-parenteral 
ampicillin 50mg/kg or benzyl 
penicillin 50,000 units per kg im/iv 
every 6 hours for atleast 5 days. 
Gentamicin 7.5 mg/kg im/iv once a 
day for 5 days. 
Severe pneumonia-admission- iv 
ampicillin 50 mg/kg every 6 hours, inj 
. Gentamicin to be added after 48 hrs 
if no improvement. 
 Very severe pneumonia-iv ampicillin 
50 mg/kg every 6 hourly and inj. 
Gentamicin 7.5 mg/kg/day once a day 
is started together. 
 
Table 4: Treatment of pneumonia according to WHO and INDIACLEN. 
INDICATIONS OF ADMISSION IN HOSPITAL: (19) 
Age less than 2 months 
Toxic appearance 
Hypoxemia 
Oxygen saturation <92% 
Cyanosis 
Respiratory difficulty 
Apnoea 
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Grunting 
Nasal flaring 
Dehydration,vomiting or poor feeding 
Immunocompromised status 
Failure to respond to oral antibiotics 
Inadequate observation or supervision by family 
INDICATION FOR ADMISSION IN INTENSIVE CARE UNIT: 
Pao2/ fio2< 250 
Mechanical ventilation 
CXR showing bilateral, multilobar pneumonia with increase in size of the 
opacity> 50% in 48 hrs prior to admission. 
Hypotension 
Vasopressor requirement 
Acute renal failure 
 
MANAGEMENT OF PNEUMONIA IN CHILDREN MORE THAN 5 
YEARS: 
 
The cause of pneumonia in children above 5 years are similar to adults 
including pneumococci and mycoplasma. If a patient does not improve with 
antibiotics or there are clinical features suggesting of atypical organisms, a 
course of atypical antibiotics may be given to these patients.(18) 
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MONITORING OF RESPONSE: 
Clinical improvement may take upto 48-96 hrs. Fever can last upto 2-4 
days, leucocytosis usually normalises by day 4, abnormal physical findings 
may persist for more than 7 days. Most non severe CAP showclinical 
resolution of symptoms in 2-3 days. Radiographs may worsen even though 
clinical picture is improving and CXR usually returns to normal within 6 weeks 
in patients and hence there is no role of follow-up CXR to look for recovery. 
 
CAUSES OF FAILURE TO IMPROVE: 
The possible cause for failure to improve is inadequate therapy which 
may be due to inappropriate antibiotic selection, inappropriate dosing and poor 
compliance. It can also be due to development of complications like empyema 
or lung abscess. If there is impaired host mechanism or there is development of 
drug resistance in the community, there may be delayed response or poor 
response. Non-bacterial pneumoniahas longer course than expected. Bronchial 
obstruction due to endobronchial lesions, foreign body or mucus plug and pre-
existing lung diseases like cystic fibrosis, ciliary dyskinesia or bronchiectasis 
may take longer than usual to improve. 
 
SUPPORTIVE THERAPY: 
Although antibiotics are the mainstay of the treatment, children should 
be given supportive therapy for the associated problems. Children with 
pneumonia may have fever, poor oral intake, vomiting, electrolyte disturbance, 
hypoxia and respiratory failure. It takes some time for the antibiotics to act. 
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Fever should be treated with paracetamol in the doses of 10-15 mg/kg/ 
dose. It can be repeated at 4-6 hours. 
Cough is other commonest symptom associated with pneumonia. Cough 
suppressants should be avoided. Common household remedies like tulsi, ginger 
and honey can be given to the child. If there is bronchospasm, inhaled 
bronchodilators like salbutamol can be given (20). 
Vomiting in pneumonia usually follows coughing and does not require 
any specific treatment. If there is persistent vomiting, antiemetic can be given 
once acidosis, electrolyte disturbances and CNS causes are ruled out. 
Associated comorbid conditions like diarrhoea, malnutrition, congenital 
heart diseases, immunodeficiency increases the case fatality in children with 
pneumonia. 
There may be hyponatremia due to inappropriate ADH secretion. A 
careful monitoring and fluid restriction is the intervention required in these 
children. 
Hypoxia may be present in children with severe pneumonia. If 
untreated, it may be associated with increased case fatality rates. Oxygen 
should be administered to all children with severe tachypnea (RR>70/min), 
chest in drawing, poor feeding or cyanosis. Oxygen may be administered by 
nasal prongs, nasopharyngeal tubes (low flow i.e. 1-2 L/min), oxygen hood, or 
face mask (high flow 4-8 L/min).Small children tolerate oxygen with hood 
better than nasal / nasopharyngeal cannula/ face mask. However, it should be 
kept in mind that oxygen saturation gives idea about oxygenation and does not 
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give any idea about carbon di oxide; even with respiratory failure, the 
saturation may be normal with high flow oxygen inhalation. Therefore, it is 
advised that in critically ill children, a baseline monitoring of arterial blood gas 
should be done(13). 
Feeding requires close attention particularly in developing countries. 
Even anorectic children accept breast milk. All feeding should be given at 
greater than usual frequencies. If they unable to suck at breast, expressed breast 
milk should be given with a cup and spoon. In children with pneumonia not 
requiring oxygen frequent small energy dense feeds should be given. Children 
sick enough to need oxygen usually do not tolerate oral and nasogastric 
feedings, thus requiring intravenous fluids. In a small proportion of children, 
pneumonia persist despite responsible antibiotic therapy. Unusual etiological 
agents such as Chlamydia, pneumocystis, mycobacterium tuberculosis or 
foreign bodies may be involved in those instances. The latter possibilities 
should be explored. (24) 
 
PREVENTION OF PNEUMONIA: 
Routine immunisation against pertussis, measles has decreased 
significant number of deaths due to community acquired pneumonia. The 
common pathogens like H. Influenza and pneumococci causing pneumonia are 
also vaccine preventable. In western countries with routine use of H. influenza 
type b vaccine, the pneumonia and related deaths due to H. influenza have 
dropped significantly. Vaccines against pneumococci are also effective in 
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preventing invasive diseases due to pneumococci. Therefore, these vaccines 
should be administered preferably to all children. (40) 
 
DRUGS USED IN THIS STUDY: 
Aminopenicillins:  
Aminopenicillins share the same basic core structure as ampicillin (2-
amino derivative of benzyl penicillin). They feature a positively charged amino 
group that makes it easy to enter bacterial porin channels but does not protect it 
against the action of bacterial beta-lactamases. They have broad-spectrum 
activity against both gram-positive and gram-negative bacteria and their 
potency is enhanced by beta-lactamase inhibitors like clavulanic acid. They are 
very useful in the management of respiratory infections. The aminopenicillins 
include ampicillin, cyclacillin, amoxicillin, pivampicillin, andbacampicillin. 
Bacampicillin and pivampicillin are pro-drugs of ampicillin. Ampicillin was 
the first amino penicillin produced (1961). It is active against both Gram-
positive and Gram-negative bacteria including S. pneumoniae and H. 
influenzae in respiratory tract infections. It is also effective against bacteria 
causing urinary tract infections, meningitis, salmonellosis and endocarditis. Its 
spectrum of activity is enhanced by combination with sulbactam, a beta-
lactamase inhibitor. It is available in oral and intravenous formulations. Oral 
bioavailability is 40%. About 15-20% of ampicillin is bound to plasma protein. 
About 12-50% of the drug undergoes hepatic metabolism. The biological half-
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life is about 1hour. Seventy-five to 85% of drug is excreted unchanged in the 
urine. (21) 
AMOXICILLIN: 
Amoxicillin is a 6-aminopenicillanic acid (6-APA) and usually the drug 
of choice within the amino penicillin class for the treatment of respiratory 
infections because of its better absorption when taken orally (95% absorbed). 
Parenteral preparation is available for intramuscular and intravenous use. Less 
than one-third is metabolized in the liver and more than half is excreted 
unchanged in the urine. It has a half-life of 61.3 minutes. Amoxicillin is a 
moderately broad spectrum antibiotic against susceptible Gram-positive and 
Gram-negative bacteria including Streptococcus, Bacillus subtilis, 
Enterococcus, Haemophilus, Helicobacter and Moraxella. Citrobacter, 
Klebsiella, Pseudomonas aeruginosa, some E. coli and Staphylococcus aureus 
are resistant to it. Combination of Amoxicillin with a beta- lactamase inhibitor 
like clavulanic acid (Co-Amoxiclav) improves its spectrum of activity. Drug-
drug interactions with anticoagulants (e.g. Warfarin), allopurinol, methotrexate, 
uricosuria drugs and typhoid vaccine have been observed with Amoxicillin. It 
comes in oral suspension (for young children) and capsule. It is also available 
as salt for parental administration. (21,22) 
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REVIEW OF LITERATURE 
 M.Atkinson, M. Lakhanpal, A. Smyth conducted a multi-centric 
pragmatic randomized controlled equivalence trial to ascertain whether 
therapeutic equivalence exists for the treatment of community acquired 
pneumonia by oral and intravenous routes. This study was the first of 
the kind in comparing oral and intravenous antibiotics. This study was 
conducted in eight pediatric centers in England. 246 children who had 
fever, respiratory symptoms and radiologically confirmed pneumonia 
were included in the study. Those children with wheeze, oxygen 
saturation <85%, those in shock, immunodeficiency, chronic lung 
condition and age less than 6 months were excluded from the trial. The 
children were randomized to receive oral amoxicillin for 7 days or IV 
benzyl penicillin. The primary outcome of this study was the time foe 
temperature to be < 380c for 24 hours and cessation of oxygen 
requirement. Secondary outcomes were time in the 
hospital,complications, duration of oxygen requirement and time to 
resolution of illness.The result of the study showed equivalence between 
oral amoxicillin and intravenous penicillin. The median time for the 
temperature to come down was 1.3 days in both the groups (P 
value<0.001). Three children in the oral group were changed to IV 
antibiotics and seven children in the intravenous group were changed to 
different antibiotics. The time for complete resolution was around 9 
days in both the groups. This trial concluded that oral and intravenous 
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penicillin are equivalent in the treatment of community acquired 
pneumonia and thus oral amoxicillin can be preferred as it is painless 
and non-invasive treatment and also reducing the direct and indirect 
costs of treating pneumonia in the population (33). 
 AddoYobo et al conducted a multi-centric, randomized, open label 
equivalency study carried out at four geographically dispersed countries 
Bangladesh, Egypt, Ghana and Vietnam between 2005 and 2008to 
determine whether oral amoxicillin and parenteral penicillin were 
equivalent in the treatment of severe pneumonia in children aged 3-59 
months.873 children were included in the study based on the case 
definition given by WHO. Evaluation was carried out at 1,2,3,6 and 14 
days to look for cumulative treatment failure and relapse rates. The 
primary outcome of the study was the treatment failure at 48 hrs. A 
secondary endpoint was treatment failure between day 6 and day 14. 
This study found 19% failure rates in each group. The most common 
reason for treatment failure was the persistence of lower chest indrawing 
at day 6, being abnormally sleepy and central cyanosis. The overall 
failure rates ranged between 6.4% to 13.2% and this study demonstrated 
that home based treatment of severe pneumonia can be applied to a wide 
variety of settings. This study also demonstrated high rates of treatment 
compliance for twice daily dosing of amoxicillin. There were no deaths 
during this study and none had serious adverse effects following drug 
administration. (25) 
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 Hazir et al carried out a randomized, open label equivalency trial at 
seven sites at Pakistan comparing hospitalization with parenteral 
penicillin to home treatment with oral amoxicillin.  2037 Children of age 
3-59 months with chest indrawing pneumonia were randomized to 
treatment in hospital with two days of injectable penicillin followed by 
three days of oral amoxicillin or were sent home with a five day twice 
daily course of oral amoxicillin. Follow-up were done at 1,3,6 and 14 
days of enrolment. The primary outcome of this study was treatment 
failure by day6. The secondary outcome of the study was treatment 
failure between day 6 and day 14.There were 8.6% failure in 
hospitalized group and 7.5% in the ambulatory group. 5 children died 
during this study (4 in hospitalized group and 1 in ambulatory group). 
But none of the deaths were related to treatment allocation. There were 
no adverse reactions reported in this study.They also found several 
baseline characteristics predictive of treatment failure namely young 
infancy (3-5 months), being significantly underweight for age and very 
fast breathing. The reason for treatment failure was either due to 
development of danger signs or persistence of lower chest retractions. 
Also this study demonstrated that antibiotic usage 7 days prior to 
randomization was a significant factor affecting the primary outcome. 
(26) 
 A study in England was conducted in 2007. It compared oral amoxicillin 
with intravenous penicillin in the management of severe pneumonia. 
36 
 
The randomized controlled, non-blinded equivalence trial was 
conducted in eight Pediatric centers. Children were randomly assigned 
to a 7day treatment of either oral amoxicillin or iv benzyl penicillin. The 
primary outcome was the time required for temperature to be below 38 c 
for 24 hours. The study found the two treatments to be equivalent, each 
having a median of 1.3 days to achieve the primary outcome. The study 
recommended that children can be treated with oral amoxicillin instead 
of IV benzyl penicillin as oral treatment was both painless and non- 
invasive. (27) 
 Archana B Patel,Akash bang,Meenu Singh, Ashraf Malik et al 
(2015)compared the clinical and cost outcomes of a seven-day treatment 
with the first 48hrs of treatment given in the hospital(hospital group) or 
at home (home group). It was anOpen label, multi-centric, two arm 
randomised control trial at six tertiary hospitals in India.  A total of 1118 
children aged 3-59 months with chest indrawing pneumonia were 
randomized to home and hospital groups. Clinical outcomes, treatment 
adherence, and patient safety were monitored through home visits on 
day 3,5,8 and 14 with an additional visit to home group after 24 hours. 
The primary outcome of this study was treatment failures upto 7 days 
and secondary outcome was treatment failures between 8 and 14 days. 
The cost outcomes included direct medical, direct non-medical and 
indirect costs.Overall treatment failures were around 11.5%. The 
predictors of treatment failure were age of 3-11 months, receiving 
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antibiotics 48 hrs prior to randomization and use of high polluting fuels. 
This study concludes that cost of treatment of severe pneumonia with 
oral amoxicillin who were initially admitted for 48 hours and then home 
based for 5 days was significantly higher than children treated with oral 
amoxicillin for 7 days at home. (28) 
 Campbell et al. conducted a quasi-randomized control trial with chest in 
drawing pneumonia in Gambia comparing oral cotrimoxazole against 
intravenous procaine penicillin.134 children of age group 1 months-4 
years with acute respiratory illness less than 1 week with signs of 
respiratory distress (intercostal indrawing and nasal flaring) were taken 
for the study. Children were randomly allocated to 5daycourse of oral 
cotrimoxazole and single IM injection of procaine penicillin followed by 
5 days of oral amoxicillin. There was no difference in symptoms, signs 
or laboratory findings and no difference in terms of final outcome after 2 
weeks of follow up. (27) 
 Agweyu et al. did an open – label, multicenter, randomized controlled 
non-inferiority trial at 6 Kenyan hospitals. Children of age 2-59 months 
with severe pneumonia were taken for the study. One group of children 
received oral amoxicillin (40-45mg/kg) or intramuscular benzyl 
penicillin at 50,000 IU/kg 4 times a day. Primary outcome is treatment 
failure measured at 48 hours. Treatment failure was 11.4% and 11.0% in 
oral and intravenous group respectively.4 children died during the study 
38 
 
of which 3 belonged to benzyl penicillin group. The presence of wheeze 
is associated with less treatment failure in this study. (29) 
 P.K. Lorgelly et al.  conducted a cost- minimization analysis alongside a 
randomized controlled non-blinded trial in eight pediatric centers in 
England.232 children diagnosed with pneumonia were admitted and 
randomized to receive oral amoxicillin or intravenous benzyl penicillin. 
This study considered the cost of health service, patients and society 
from pre-admission until the child was fully recovered. The drugs had 
equivalent efficacy. Children in hospital admission had significant 
longer duration of hospital stays and more expensive than oral 
treatment. (30) 
 A meta-analysis of four randomized controlled trials was conducted to 
determine the efficacy of oral antibiotics in under-five children with 
pneumonia and chest indrawing.4 clinical trials (Addo-Yobo et al, Hazir 
et al, Campbell et al, and Agweyu et al) involving 4400 children who 
were diagnosed to have severe pneumonia but were feeding well and not 
hypoxic were included for the study. In two studies oral antibiotics were 
administered on ambulatory basis while in two, oral antibiotics were 
used in hospitalized children. The primary outcome measure was 
treatment failure (persistence of symptoms, development of danger signs 
hypoxia and withdrawal from the study). Secondary outcome were 
relapses, death, need for hospitalization and severe side effects. All the 4 
RCTs included children under 5 years of age. The proportion of infants 
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were similar in both groups (OR 1.03; CIO.86,1.22). The other baseline 
characteristics like sex distribution, nutritional status, presence of 
wheeze were similar in both groups. Three studies compared oral 
amoxicillin with parenteral penicillin/ ampicillin. Only one study 
compared cotrimoxazole with procaine penicillin. Failure rate in oral 
antibiotic group was 13% and in parenteral antibiotic group was 13.8%. 
Relapse rates, hospitalization or serious adverse effects were same in 
both groups. The results of this analysis was not influenced by treatment 
in hospital or treatment in society, type of antibiotics, etiological agents 
and presence of wheeze. This analysis concluded that children with 
chest indrawing pneumonia from low and middle income countries with 
low HIV prevalence may be managed with oral antibiotics at home with 
monitoring by health care workers (31). 
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STUDY JUSTIFICATION 
 Various studies done worldwide have proven that oral amoxicillin can be 
safely used instead of parenteral penicillin in children with chest indrawing 
pneumonia of age 3-59 months based on which WHO revised guidelines were 
made. However, these results are not applicable to all settings, especially where 
the risk of mortality is high such as those with very severe disease or child 
having severe malnutrition. 
 INDIACLEN task force on pneumonia states that unless the evidence is 
more compelling and is replicated to all settings, there is no justification in 
changing the current practice of hospital admission, detailed assessment, 
injectable antibiotics and supportive therapy. This study is mainly carried out to 
compare the efficacy of oral antibiotic against IV antibiotic in our population. 
If this study proves non-inferiority of oral amoxicillin over parenteral 
penicillin, safe community level management can increase the number of 
children benefitted from our care. Hospitalization can lead to many 
disadvantages like nosocomial infections, increased health care costs, indirect 
expenses etc. that can be avoided by ambulatory management (2,23). 
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AIMS AND OBJECTIVES 
 
This study is conducted to compare the efficacy and safety of oral 
amoxicillin against intravenous ampicillin in children of age 3- 59 months with 
chest indrawing pneumonia according to revised WHO guidelines. 
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METHODOLOGY 
STUDY DESIGN:Randomized controlled trial-non inferiority design, with 
allocation concealment and block randomization. 
STUDY SETTING: General pediatric wards ofInstitute of child health and 
hospital for children. 
STUDY PERIOD: November 2016- September 2017 
STUDY POPULATION: 
INCLUSION CRITERIA:  All children of age 3-59 months who have chest 
indrawing pneumonia according to WHO classification. 
EXCLUSION CRITERIA: 
1. Known cases of immunodeficiency. 
2. Asthma. 
3. Children who had antibiotics>48 hrs for the current illness. 
4. Lower chest retractions responding to nebulisation. 
5. H/o cough /difficulty in breathing for more than 2 weeks. 
6. Severe acute malnutrition. 
7. Those not given consent for the study. 
 
SAMPLE SIZE: 100 (convenient sampling). 
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MANOEUVRE 
The study was commenced after obtaining approval from the Institution 
Ethical committee. All children of age 3-59 months admitted for chest 
indrawing pneumonia without any danger signs as classified by WHO were 
admitted and considered for recruitment. The whole procedure was explained 
to the parents and consent obtained. 
The baseline characteristics of the child like name,age in months, sex 
were noted. Duration of symptoms of cough and cold, fever, fast breathing, 
noisy breathing whether present or not, and any other symptoms were also 
noted. Any past history of admissions, drug intake and any previous surgeries 
were enquired. 
Anthropometric measurements of the child were made. Height of the 
child is measured using standard methods. The length of the children less than 
2 years was measured using an infantometer. The height of the children ≥2 
years was measured in stadiometer without shoes and head, shoulders, buttocks 
and heels touching the board. Weight of the children was measured using an 
electronic weighing scale. Weight for age, Height for age and Weight for 
length/height were plotted using WHO growth charts. Children with severe 
acute malnutrition were excluded from the study. Children with moderate acute 
malnutrition were included in the study.  
The whole procedure was explained to the recruited parents. Clinical 
data of the children like temperature, heart rate, respiratory rate, presence of 
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any added sounds were noted at the time of admission. Axillary temperature of 
the children was recorded at admission using a digital thermometer. 
Temperature more than 370c was taken as fever. Heart rate is auscultated for 
one full minute. Age- wise cut-off values were used to classify normal heart 
rate and tachycardia. The child was undressed up to waist and child was seated 
in non- threatening position (preferably in mother’s lap) to count respiratory 
rate. It was counted by placing hand on the chest and the respiratory 
movements were counted for one full minute.  
Chest indrawing is the inward movement of lower chest wall when the 
child breathes in and it is a sign of respiratory distress. Both intercostal and 
subcostal retractions are taken into account. Those children with lower chest 
retractions responding to bronchodilator nebulization were excluded from the 
study. The presence of added sounds and type of added sounds (crackles, 
wheeze, or both) were also documented. 
The children were randomized in the ratio of 1:1 using computer 
generated randomization codes with the block size of 10. Random sequence 
was generated by one of the co-guides and placed in serially numbered opaque 
sealed envelopes. The children were assigned to treatment by the principal 
investigator using consecutive envelopes. The oral group children were given 
oral amoxicillin 80 mg/kg/day in two divided doses for 5 days and in 
intravenous group, ampicillin 200 mg/kg/day in three divided doses was given 
for 5 days. These children were also subjected to blood and radiological 
investigations based on the unit protocol. 
45 
 
The children were followed up after 48hrs and 5 days for the clinical 
improvement. Data like temperature, respiratory rate, heart rate, added sounds 
and persistence of retractions after 48 hours were noted. Any development of 
danger signs, other new symptoms, adverse reactions to the drug were also 
recorded. The supportive measures given to the child like antipyretics, 
nebulization were taken into account. Any detoriation after 48 hours were noted 
and time taken for the discharge of the study children were documented. All the 
children were followed up till discharge/ death. 
The primary outcome of the study is taken as absence of improvement or 
detoriation in the study children that warrants escalation of antibiotics in either 
arm at the end of 48 hours of initiation of therapy. 
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STATISTICAL ANALYSIS 
The data from the forms were entered in the excel sheet. Statistical 
analysis of the data was performed by SPSS software version 21. The primary 
outcome was measured in both the limbs and expressed as risk ratio and risk 
difference between the two limbs. Analysis was made to compare the baseline 
characteristics of two groups and to find predictors of poor outcome of the 
disease. 
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     RESULTS 
A total of 100 children of age 3-59 months with chest indrawing pneumonia 
were included for the study. 
AGE AND GENDER DISTRIBUTION: 
Table 5 shows the age and sex distribution of the study population: 
AGE MALE 
n(%) 
FEMALE 
n(%) 
TOTAL 
n(%) 
< 12 MONTHS 24 (24%) 10(10%) 34(34%) 
1-5 YEARS 37 (37%) 29(29%) 66(66%) 
TOTAL 61(61%) 39(39%) 100(100%) 
 
                                        Table 5: Age and sex distribution 
The median (IQR) age of the study population was 15.5 months.  
(11-25.5)  
Male: Female ratio was 1.56:1. 
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PRESENTING COMPLAINTS: 
 
Most of the children presented with fever, cough and cold and 
breathlessness of variable duration. Some children also had other symptoms 
like vomiting, loose stools and other symptoms. 
Mean (SD) duration of cough and cold was 4.86 (1.975) days. 
The mean (SD) of fever was 4.47 (2.129) days. 
Median (IQR) duration of fast breathing was 2.5 (2-3) days. 
None had noisy breathing. 
 
The following figure shows other symptoms seen in the study population: 
           
 
                    Figure 5: Other symptoms in study population 
90% of the study population had no other symptoms. 5% had vomiting of 
feeds. 3% had loose stools. And 2% had other symptoms. One child presented 
with simple febrile seizures and the other child had hydrocele. 
90%
5%
3%2%
OTHER SYMPTOMS
none vomiting loosestools others
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PAST HISTORY: 
Only 3 out of 100 children had a significant past history and had previous 
hospitalization. One child was admitted for atypical febrile seizures and was on 
oral phenobarbitone. Another child was aknown case of seizure disorder on 
oral sodium valproate. One another child was a known case of posterior 
urethral valve on regular surgical follow up and not on any drugs. 
ANTHROPOMETRY: 
HEIGHT FOR AGE: 
The following pie chart shows height for age of the study population: 
 
Figure 6: Height for age. 
91% of the children had a normal height and 9% of them are stunted for 
age. 
 
9%
91%
STUNTED NORMAL
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WEIGHT FOR AGE: 
The following chart shows the weight for age of the study population: 
 
                                       Figure 7: Weight for age 
68% of the study population had a normal weight. 28% falls under 
underweight and 4% of them were severe underweight according to WHO 
standards. 
WEIGHT FOR LENGTH/HEIGHT: 
The following chart shows the weight for length distribution of the study 
population:  
 
Figure 8: Weight for length/height 
4%
28%
68%
SEVERE UNDERWEIGHT UNDERWEIGHT NORMAL
39%
61%
MODERATE ACUTE MALNUTRITION NORMAL
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Out of 100 study children, 39 children came under moderate acute 
malnutrition category. 61 children had normal weight for length/height. 
CLINICAL DATA ON ADMISSION: 
 All children had respiratory distress and tachypnea according to their 
age at the time of admission.  The following bar diagram depicts the percentage 
of children with respiratory distress, normal/ increased heart rate and with / 
without fever.  
 
                  Figure 9: Clinical data on admission(temp, RR, heart rate) 
 15% of the population had normal temperature. 85% had fever. Of these 
seven children had very high temperature (>38 c). 59% of children had normal 
heart rate and 41% had tachycardia. None of the children had bradycardia. All 
the children had increased respiratory rate on admission. 
15
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ADDED SOUNDS: 
Presence or absence of added sounds in the form of crackles or wheeze 
were noted. The following chart shows the percentage of children with 
crackles/ wheeze/ both. 
 
                           Figure 10: Added sounds at the time of admission 
Majority of the children had crackles alone at the time of admission 
(68%). 20% of the children had no added sounds. 12% of the children had both 
crackles and wheeze. 
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INVESTIGATIONS: 
XRAY FINDINGS: 
28% of the children had no findings in the xray.40% of the children had 
x-ray finding suggestive of pneumonia (37%- bronchopneumonia, 3%- patchy 
consolidation). 32% of the children had bilateral hyperinflation. 
 
 
                     Figure 11: chart showing the X-ray findings 
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TOTAL AND DIFFERENTIAL COUNT: 
Total count was raised in 37% of the children. Among 37% of those 
with raised counts, 33 children had polymorphonuclear leukocytosis, and 4 
children had lymphocytosis.63% of the children had normal counts. The 
following chart depicts the percentage of children having normal/ raised counts 
and it also shows, among those with raised counts, whether it is 
polymorphonuclear leukocytosis or lymphocytosis. 
 
 
                 Figure 12: Total and differential count in the study population 
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C- REACTIVE PROTEIN: 
C reactive protein, an acute phase reactant is the marker of 
inflammation. It indicates the presence or absence of infection. CRP is positive 
in 78% of the cases and negative in 22%. The following diagram shows the 
percentage of children in who CRP is positive. 
 
Figure 13: C –reactive protein in the study population 
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CO INTERVENTIONS: 
 Most of the children received antipyretics and nebulization as supportive 
management.68% of the children received only paracetamol. 26% of the 
children received 3% saline nebulization. 4 children received salbutamol 
nebulization. Two children received both nebulization and nasal oxygen for 
supportive management. The bar chart shows the percentage of children who 
received supportive measures.  
 
 
             Figure 14: co interventions given to the study population 
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CLINICAL DATA AFTER 48 HOURS OF ADMISSION: 
 Only one child left the study before 48 hours whose clinical data could 
not be collected. 
TEMPERATURE: 
Most of the children became afebrile at the end of 48 hours. 86 children were 
afebrile and 13 children continued to have fever spikes. The pie chart depicts 
the percentage of children with normal/ raised temperature after 48 hours. 
 
 
Figure 15: Temperature at the end of 48 hours. 
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RESPIRATORY RATE: 
The respiratory rate should come down at the end of 48 hours. Failure of 
this indicates treatment failure. In 74 children, who initially had tachypnea, 
respiratory rate became normal. In 17 children, the RR decreased but doesn’t 
fall in normal range. In 4 children, it remained same. It neither increased nor 
decreased. In 4 children the respiratory distress worsened with increase in rate. 
The following bar diagram shows the respiratory rate in children after 48 hours 
of admission.  
 
                        Figure 16: Respiratory rate at the end of 48 hours 
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HEART RATE: 
90 children had normal heart rate and 9 children persisted to have 
tachycardia. The pie chart shows the percentage of children with normal heart 
rate and tachycardia. 
 
                    Figure 17: Heart rate at the end of 48 hours. 
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ADDED SOUNDS AND RETRACTIONS: 
82 children did not have any added sounds at the end of 48 hours. 15 
children continued to have crackles and 3 children had both crackles and 
wheeze.78 children had no retractions and 21 had retractions at the end of 48 
hours. The clustered bar chart shows the percentage of children in whom 
retractions persisted and also the type of added sounds that was present at the 
end of 48 hours. 
 
 
 
             Figure 18: Added sounds and retractions at the end of 48 hours. 
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OUTCOME OF THE STUDY: 
At the end of 48 hours, of the total 99 children who were on follow up, 
81 children improved in both limbs and in 18 children treatment was escalated 
in both the limbs. None of the child expired during the study. This pie chart 
shows percentage of children who showed improvement and those in whom 
treatment was escalated. 
 
 
                         Figure 19: outcome at the end of 48 hours 
DETORIATION AFTER 48 HOURS: 
2 children detoriated after 48 hours in whom treatment was escalated  
and 97 children showed no detoriation. 
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FINAL OUTCOME OF THE STUDY POPULATION: 
None of the children recruited for the study expired during the study 
period. 75 children were successfully discharged at 5 days after admission. 22 
children were discharged at around 7-10 days . 3 children left the study before 
5 days of which one child left before 48 hours. There was no adverse reactions 
reported during this study. 
 
 
                              Figure 20: Final outcome of the study 
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COMPARISON OF BASELINE VARIABLES OF BOTH LIMBS: 
Various individual parameters that can influence the outcome of the 
disease like age of the child, nutritional status, duration of the symptoms like 
fever, cough and cold, presence of added sounds, Xray findings, co 
interventions provided for the children in both the limbs are compared to find if 
there is any significant difference in the baseline characteristics that can alter 
the outcome of the disease. The following table shows the comparison of 
baseline characteristics between the two groups: 
PARAMETER ORAL AMOXYCILLIN 
IV 
AMPICILLIN X
2 
P 
VALU
E 
INFANCY 
18/50 16/50 0.178 0.624 
COUGH AND 
COLD 
DURATION 
4.74(1.498) 4.98(1.964) 0.214 0.624 
MODERATE 
ACUTE 
MALNUTRITION 
23/50 16/50 2.60 0.151 
FEVER 42/50 43/50 0.078 1.000 
WHEEZE 6/50 6/50 0.0 1.000 
CXR pneumonia 22/50 18/50 0.667 0.414 
CRP POSITIVITY 
339/50 39/50 0.0 1.000 
NEBULISATION 14/50 39/50 0.190 0.663 
 
                                  Table 6: comparison of baseline variables 
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This table clearly shows that  there is no significant difference in the 
baseline characteristics between two limbs. 
COMPARISON OF INTERVENTION WITH OUTCOME AT THE END 
OF 48 HOURS: 
Each arm (oral & parenteral) had 50 children in the group. Among the 
oral amoxycillin group, 1 child left the study before 48 hrs so that outcome 
cannot be measured in that child.of the total 49 children in oral amoxycillin 
group, 41 children improved at the end of 48 hours. In 8 children, treatment 
was escalated to parenteral antibiotic.among 50 children in IV ampicillin 
group, 40 children improved with treatment and in 10 children, it is escalated to 
higher antibiotics.The treatment failure is 16.3% ( 8 out of 49) in oral 
amoxycillin group and 20.3%(10 out of 50)  in IV ampicillin group.  The table 
7 compares the outcome of the disease in both the limbs which is the primary 
measure of this study. 
 
Table 7: Comparison of  outcome at the end of 48 hours in both limbs 
 
 
 
ORAL 
AMOXYCILLIN 
N(%) 
INTRAVENOUS 
AMPICILLIN 
N(%) 
TOTAL 
N(%) 
OUTCOME 
AT THE 
END OF 48 
HOURS 
IMPROVED 41(41%) 40(40%) 81(81%) 
 TREATMENT 
ESCALATED 8(8%) 10(10%) 18(18%) 
 TOTAL 49(49%) 50(50%) 99(99%) 
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The results can be interpreted in the form of Risk difference between two 
limbs. 
(8/49) - (10/50)= 0.1632-0.2000= - 0.0368.  
Risk ratio is calculated as  (8/49) / (10/50)=0.1632/0.2000= 0.8163. 95% CI 
(0.3517-1.8949). 
Chi square tests were performed on these data to find the significance in 
failure rate of these two limbs.The x2value is 0.472 and p value is 0.636 which 
is not significant. 
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PREDICTORS OF POOR OUTCOME AFTER 48 HOURS IN 
CHILDREN: 
Analysis were done to identify the individual parameters that can affect 
the outcome of the disease in the children. Age of the child, duration of 
symptoms, CXR findings, presence of wheeze in the child, nutritional status 
were taken into account . 
AGE OF THE CHILDREN: 
This study was carried out in children from age 3 months to 5 years. For 
analysis, they were grouped as infants (3-11 months ) and non infants (>12 
months) because in various trials conducted before, infancy is an important 
predictor in treatment failure. In the following table , data were analysed to find 
whether age of the child affects the outcome of the disease. 
  IMPROVED TREATMENT ESCALATED TOTAL 
AGE OF 
THE 
CHILDREN 
3-11 months 26 8 34 
 >12 months 55 10 65 
 TOTAL 81 18 99 
                                             
X2 = 0.995 ; p =0.318 
Table 8: Age of the children on the outcome at 48 hours 
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Only 34% of the study population belonged too age 3-11 months. Of 
these, 26 children improved with antibiotics and only in 8 children the 
treatment was escalated too higher antibiotics in their respective arms. The X2 
value is 0.995 and the p value is 0.318 which is not significant. 
DURATION OF SYMPTOMS: 
The duration of cough and cold and respiratory distress during the time 
of admissions are analysed to predict their influence on the outcome of the 
children.  
The mean duration of illness in those who improved and in those 
treatment escalated were calculated. 
OUTCOME 
AT 48 HOURS 
NUMBER 
OF 
CHILDREN 
MEAN STD.DEVIATION STD.ERROR  MEAN 
IMPROVED 81 4.70 1.993 0.215 
TREATMENT 
ESCALATED 18 5.44 2.093 0.493 
 
Table 9: Duration of symptoms on outcome at 48 hours 
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Totally 81 children improved and in  18 children treatment were 
escalated. The mean duration of symptoms was calculated. It was 4.70 in 
improved group and 5.44 days in children. The p value is 0.957 which is not 
significant. 
NUTRITIONAL STATUS: 
This trial excluded the children with severe acute malnutrition as they 
must be admitted and started on intravenous antibiotics irrespective of the 
severity of illness. So, the study population was classified as those with 
moderate acute malnutrition and those who had normal weight for length to 
analyse their predictability in treatment failure. 
  Improved Treatment escalated Total 
Nutritional 
status 
Moderate 
acute 
malnutrition 
30 9 39 
 Normal 51 9 60 
 Total 81 18 99 
 
X2=1.037 ; p = 0.309 
           Table 10: Nutritional status on outcome at 48 hours. 
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 This table shows that , of the total 39 chiildren who had moderate acute 
malnutrition, 30 children and in only 9 children treatment was escalated.In 
normal children also, 9 children did not respond to treatment. The X2 value is 
1.037 and p value is 0.309 which is not significant. Thus, nutritional status of 
the child does not have any significant influence over the disease outcome. 
DURATION OF FEVER: 
The duration of fever was taken into account because in previous 
studies, persistance of fever beyond a period of 6 days became a important 
predictor in the poor outcome in those children. 
 
At the end of 
48 hours Improved 
Treatent 
escalated Total 
Fever Present 12 2 14 
 Absent 69 16 85 
 Total 81 18 99 
                                             
X2 =0.166 ; p =0.683 
           Table 11: Duration of fever on outcome at 48 hours 
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Fever persisted in 14 children at the end of 48 hours. Of those, only in 2 
children treatment were escalated and 12 children improved with antibiotics. 85 
children did not have fever at the end of 48 hours. Eventhough fever subsided, 
in 16 children, treatment was escalated was various other reasons, mainly 
persistence of retractions. The X2 value is 0.166 and p value is 0.683 which is 
not significant.Thus duration of fever does not alter the outcome of the disease. 
PRESENCE OF WHEEZE: 
Most of the children included in the study had only crackles at the time 
of admission. But some children presented with both crackles and wheeze. 
Analysis was done to find out whether presence of wheeze affects the outcome 
at the end of 48 hours. 
  IMPROVED TREATMENT ESCALATED TOTAL 
WHEEZE PRESENT 7 5 12 
 ABSENT 74 13 87 
 TOTAL 81 18 99 
 
X2 = 5.063 ; p = 0.024 
Table 12: Presence of wheeze on the outcome at 48 hours. 
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Totally 12 children recruited had both crackles and wheeze. Of these, 7 
children improved with treatment and in 5 children treatment were escalated. 
The X2 value is 5.063 amd p value is 0.024 which is significant. so, presence 
of wheeze in children admitted for pneumonia is a predictor of poor outcome in 
our population. 
CXR FINDINGS: 
CXR findings are not necessary for the initiation of therapy at the 
community level. Presence of bronchopneumonia and patchy consolidation 
were taken as significant findings. Those children with CXR positive findings 
were  analysed for the outcome. 
 
Features  
suggestive of 
pneumonia 
Improved Treatment escalated Total 
 Present 27 13 40 
CXR Absent 54 5 59 
 Total 81 18 99 
                                           
X2 = 9.250 ; p =0.002 
Table 13: CXR findinds on the outcome at the end of 48 hours. 
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This table shows that, of the total 40 children who had CXR findings 
suggestive of pneumonia, in 13 children treatment was escalated to higher 
antibiotics, whereas in those who did not have cxr features, only  in 5 children 
treatment was escalated. The X2 value is 9.250 and p value is 0.002 which is 
significant. Thus this study shows that, those children with CXR findings take 
longer time to improve than those with who did not have CXR findings. 
To summarize,the following table tries to find the predictors of poor 
outcome of the disease. 
  
73 
 
PARAMETER CATEGORY IMPROVED TREATMENT ESCALATED X
2 P 
VALUE 
INFANCY 
INFANTS 26/34 8/34 
0.995 0.318 
>1 YEAR 55/65 10/65 
COUGH AND 
COLD 
DURATION 
 4.70(1.933) 5.44(2.093) 0.003 0.957 
NUTRITION 
MAM 30/39 9/39 
1.037 0.309 
NORMAL 51/60 9/60 
FEVER 
YES 12/14 2/14 
0.166 0.683 
NO 69/85 16/85 
WHEEZE 
YES 7/12 5/12 
5.063 0.024 
NO 74/87 13/87 
CXR 
PNEUMONIA 
POSITIVE 27/40 13/40 
9.250 0.002 
NEGATIVE 54/59 5/59 
 
Table 14: Predictors of poor outcome of the disease 
This table shows that age, symptoms duration, nutritional status and 
fever does not influence the outcome of the disease.Only presence of wheeze in 
children with pneumonia and CXR findings suggestive of pneumonia 
significantly affects the  outcome of pneumonia at the end of 48 hours. 
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DISCUSSION 
Our study revealed that there is no significant difference in the treatment 
failure rate in children of age 3-59 months with chest indrawing pneumonia 
where one group of children were treated with high dose of oral amoxycillin 
and another group treated with parenteral ampicillin. Thus this trial proved the 
non inferiority of oral amoxycillin over parenteral ampicillin and thus can be 
used in the ambulatory basis for the management of chest indrawing 
pneumonia. 
The treatment failure rate in oral amoxycillin group is 16.3% and in 
intravenous ampicillin group is 20.3% with minimum risk difference between 
two groups.The most common reason for the escalation to higher antibiotics 
was failure of improvement of symptoms rather than worsening of symptoms 
or appearance of danger signs in our study. The baseline characteristics were 
comparable in both the limbs.The presence of wheeze in the children at the 
time of admission and CXR features suggestive of pneumonia were the factors 
that significantly affected the outcome of the children in both the arms. There 
was no deaths/ adverse events reported during the study period. 
The primary outcome of our study was  in accordance with the previous 
trials done similarly comparing the oralantibiotics with parenteral antibiotics in 
pneumonia.But the failure rates were high when compared to the previous trials 
because the sample size was low and the primary outcome was measured after 
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48 hours whereas in pervious international trials, in most trials, the primary 
outcome was measured at the end of 6 days. 
A meta analysis is conducted compiling the trials from different regions 
of the world  that led to the change in the treatment protocol for children with 
chest indrawing pneumonia by WHO ( Addo Yobo et al, Hazir et al, Campbell 
et al, Agweyu et al ).Most previous trials done compared oral amoxicillin and 
parenteral penicillin. Only one trial used cotrimoxazole and procaine 
penicillin(27). However, the results were same irrespective of the group of  
antibiotic used. All the trials proved the equivalency of oral antibiotic and 
parenteral antibiotics.  
All the children were admitted in the hospital and randomized into oral 
and parenteral group in our study. In the meta- analysis, most of the trials were 
done partly / fully in hospital and only one trial was done completely as 
ambulatory basis(27). In study conducted by Addo Yobo et al, both the groups 
were hospitalized. But, the outcome was not affected in any trials because  of 
hospitalization.There were ther similar studies done in Pakistan that concluded 
that community level management is equivalent to hospital management. 
In the study conducted in India , nine pediatric centers were included in 
the study to study the equivalence of oral and parenteral treatment and also cost 
analysis in both limbs. Treatment failure were similar in both groups and 
ambulatory management was cost effective than hospitalization (direct and 
indirect health care costs). Cost analysis was not done in our study. (3) 
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In  most of the trials done before, young infants (3-11 months) , 
presence of very fast breathing were the poor predictors of outcome in both the 
limbs. In our study, both infancy and respiratory rate were not significant in 
predicting the outcome of the disease. This discrepancy can be due to the 
sample size as only 100 children were recruited for convenient sampling. Of 
the total study population , only 34 children belonged to age of 3-11 months. A 
larger sample size could have led to more number of infants included in the 
study.  
Only one study byAddo Yobo et al (25) considered the nutritional status 
of the children included in the study. But it was not a poor predictor of 
outcome. This is in concordance with our study. Children with / without 
malnutrition responded equally to the treatment. 
The presence of wheeze at the time of admission was a significant 
predictor of poor outcome in our study . Only one study done in the 
past,considered the significance of presence of wheeze at admission but it was 
not a predictor of poor outcome (29). Wheeze when present is mostly a feature 
of viral pneumonia and this could be the reason for delay in improvement in  
these children. 
 Those children with Xray findings consistent with pneumonia ( patchy 
consolidation and bronchopneumonia) took longer period for resolution of the 
disease compared to those in whom CXR was normal. WHO does not include 
CXR findings to classify pneumonia. None of the studies included in the meta-
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analysis considered laboratory/ radiological findings in the study. Previously , a 
study was conducted in Botswana in a tertiary center to predict the outcome in 
children with CXR positive pneumonia. That study showed that CXR finding 
consistent with pneumonia was an independent predictor of poor outcome in 
the children. Similar study done in India (Himachal pradesh) shows that time 
for defervescence for outcome measures were similar with consolidation, 
interstitial pneumonia or normal xrays. However, the length of  stay was 
prolonged in these children with positive CXR findings. This is consistent with 
our study. Most children with positive CXR findings were discharged around 7 
-10 days when compared to those children with normal Xrays who were 
discharged at 5 days.(38) 
 Amoxicillin and ampicillin belongs to same group of penicillins ( 
aminopenicillin). Amoxicillin have higher peak serum concentrations , larger ‘ 
area under the curve’ and greater urinary excretion than ampicillin (39). Half 
lives of both amoxicillin and ampicillin are same. However , studies shows that  
high doses of amoxicillin when given orally reaches  same peak serum 
concentration obtained by giving same dose of ampicillin intramuscularly. 
Thus amoxicillin in high doses can be used for certain infections that are 
treated with parenteral penicillin. (42) 
Thus this trial showed that high doses of amoxicillin can be used in 
place of intravenous ampicillin in the treatment of chest indrawing pneumonia 
in our population. This will minimize the hospital acquired infections , direct 
and indirect costs spent by the people for hospital admissions. 
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STUDY LIMITATIONS: 
 The main limitation of the study is the sample size. Only 50 children in 
each arm were recruited as convenient sampling. Whether  the results 
can be applicable to the entire population is not known. 
 The feeding pattern of the recruited children were not taken into 
account.Previous studies have proved the benefit of breastfeeding for 
faster recovery. 
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SUMMARY 
 Oral amoxycillin in not inferior to parenteral ampicillin in the treatment 
of children of age 3-59 months with chest indrawing pneumonia 
according to WHO guidelines. 
 The baseline characteristics of the children included does not differ 
significantly in both arms. So, both the groups were comparablewith 
respect to all characteristics. 
 Presence of wheeze at the time of enrolment not responding to 
salbutamol nebulisation and CXR findings suggestive of 
bronchopneumonia were the predictors of poor outcome in these 
children with pneumonia. 
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CONCLUSION: 
Oral amoxycillin in the dose of 80 mg/kg/day in two divided doses for 5 
days is equally efficacious and  can be safely used in children having chest 
indrawing pneumonia according to WHO clasification of age 3-59 months in 
the community level instead of hospitalisation and parenteral ampicillin. 
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DATA COLLECTION FORM 
 
IDENTIFICATION 
l. Study Id  : 
2. Name  : 
DEMOGRAPHIC CHARACTERISTICS 
3.  Age  a) DOB:_______________ 
    b) Age in months: ___________ 
    c) Category: 1) 3-12 months  2)13-36 months  3) 37-60 
months  
4. Sex : 1) Male   2) Female  3) Others 
PRESENT HISTORY 
5. Cough & cold duration - ____________ 
6. Fever – 1) Yes 2) No   If YES, duration - _____________ 
7. Fast breathing 1) Noticed 2) Not noticed  If yes, duration- _____ 
8. Noisy breathing – 1) Yes  2) No   If yes, duration _______________ 
9. Any other symptom -1)no 2) vomiting of feeds  3) loose stools  4)others 
PAST MEDICAL HISTORY 
10. Pre-existing illness – 1) Yes 2) No  If YES specify - 
______________________ 
11. Hospitalisation in past – 1) Yes 2) No If yes, reason- 
_________________ 
12. On any medication – 1) Yes 2) No If YES, specify 
_______________________ 
ANTHROPOMETRY 
13. Height/length-  in cm  cm 
     1) <-3 z score 2) -3 to -2  3) -2 to +3 4) >+3 z score 
14. Weight-  kg 
     1)<-3z score 2) -3to -2 3) -2 to +1 4) > +1 z score  
  
 
 
15. Weight for length- 1)<-3 z score 2) -3 to -2 z score 3) -2 to +1  
          4) +1 to +2 5) +2 to +3  6) > +3 z score 
CLINICAL DATA AT ADMISSION: 
16. Temperature:  1) <36.5°C    2) 36.5-38 °C        3) >38°C 
     17. Respiratory rate (per minute): ______ 
                                  1) bradypnea   2) normal   3) tachypnea 
18. Heart rate (per minute): _____1) bradycardia   2) normal   3) tachycardia 
19. Added sounds – 1) None  2) creps alone 3) creps and wheeze 
INVESTIGATIONS: 
20. CXR – 1) Normal 2) BHI  3) Patchy consolidation  
                    4) Bronchopneumonia           5) Others 
21. Total count – 1) Normal 2) Raised  
            If raised 1) Polymorphonuclear leucocytosis  2) Lymphocytosis 
22. CRP – 1) Negative 2) Positive 
23. Any other abnormal investigation - ____________________________ 
      24. TYPE OF INTERVENTION: 1) ORAL       2) PARENTERAL 
      25.co interventions: 1) antipyretics 2) saline neb 3) salb neb 4) nasal o2 
      26. any co morbid illness  1) yes    2) no 
      27.any detoriation before 24 hours?   1)yes    2) no 
CLINICAL DATA AFTER 48 HOURS OF ADMISSION: 
    25. Temperature- 1) <36.5 °C       2) 36.5-38°C          3)> 38°C 
    26. Respiratory rate (per minute): ______ 
                                 1) Normal 2) Decreased, but tachypneic       3) Same  
4) Increased 
    27. Heart rate (per minute): ___________ 
                      1) Normal 2) Tachycardia 
 28. Added sounds – 1) None  2) creps alone  3) creps and 
wheeze 
    29. Chest retractions- 1) Absent      2) Present 
 
 
    30. Any new symptom/sign/complication – 1) Yes 2) No 
         If YES, then _________________________________ 
OUTCOME: 
31. At the end of 48 hours – 1) Improved 2) Treatment escalated 
                                               a) no improvement   b) appearance of danger 
signs 
    3) Expired- Cause of death and duration of stay 
  32. Any deterioration after 48 hours 1) Yes 2) No If YES, cause and timing 
______________ 
  33. Final outcome – 1) Discharged≤ 5 days  2) discharged >5 days   3) left the study 
 4) Died 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
